Pancreatic Cancer Research

ResearcherNorthwell HealthActive in the last 2 years

Matthew John Weiss

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1052-0128; OpenAlex author ID A5102797818. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 4 papers · 2025: 4 papers

Papers 19

  1. Evaluating the Association of Area Deprivation Index (ADI) on Postoperative Outcomes in Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27996↗
  2. Impact of Environmental Quality on Pancreatic Cancer Outcomes Post Pancreatoduodenectomy: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-025-01254-4↗
  3. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  4. Standard-Adherent Surgery and Guideline-Based Therapy in Pancreatic Cancer: A Multicenter Analysis. Co-author DOI 10.1245/s10434-025-17467-7↗
  5. Machine learning to predict completion of treatment for pancreatic cancer. Co-author DOI 10.1002/jso.27812↗
  6. Outcomes of minimally invasive vs. open pancreatoduodenectomies in pancreatic adenocarcinoma: analysis of ACS-NSQIP data. Co-author DOI 10.1007/s00423-024-03454-1↗
  7. Modified 5-Item Frailty Index (mFI-5) may predict postoperative outcomes after pancreatoduodenectomy for pancreatic Cancer. Co-author DOI 10.1007/s00423-024-03483-w↗
  8. Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S. Co-author DOI 10.1007/s12029-024-01119-2↗
  9. Advance care planning in patients undergoing surgery to resect pancreatic adenocarcinoma: Underlying tension between balancing hope and realism. Co-author DOI 10.1016/j.surg.2021.08.033↗
  10. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-… Co-author DOI 10.1245/s10434-020-09201-2↗
  11. Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. Co-author DOI 10.1007/s11605-018-3894-7↗
  12. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated Wit… Co-author DOI 10.1016/j.ijrobp.2017.10.001↗
  13. Pancreaticoduodenectomy with en bloc vein resection for locally advanced pancreatic cancer: a case series without venous reconstruction. Co-author DOI 10.21037/cco.2018.01.01↗
  14. Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning. Co-author DOI 10.1148/rg.2017160054↗
  15. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery. Co-author DOI 10.1002/jso.24404↗
  16. Modified Appleby Procedure for Pancreatic Adenocarcinoma: Does Improved Neoadjuvant Therapy Warrant Such an Aggressive Approach? Last author DOI 10.1245/s10434-016-5303-3↗
  17. Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. Co-author DOI 10.2214/ajr.13.12439↗
  18. Irreversible electroporation: a novel therapy for stage III pancreatic cancer. Co-author DOI 10.1016/j.yasu.2014.05.002↗
  19. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Co-author DOI 10.1158/0008-5472.can-14-0734↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marcovalerio Melis · 7 shared papers, 2024–2025 · strength 1.59
  2. Elliot Newman · 7 shared papers, 2024–2025 · strength 1.59
  3. Abdullah Khalid · 7 shared papers, 2024–2025 · strength 1.59
  4. Danielle K. DePeralta · 7 shared papers, 2022–2025 · strength 1.54
  5. Sepideh Gholami · 6 shared papers, 2024–2025 · strength 1.39
  6. Daniel A. King · 6 shared papers, 2024–2025 · strength 1.33
  7. Shamsher Ali Pasha · 5 shared papers, 2024–2025 · strength 1.11
  8. Lyudmyla Demyan · 5 shared papers, 2022–2025 · strength 1.05
  9. Oliver J. Standring · 3 shared papers, 2024–2025 · strength 0.69
  10. Christopher Lee Wolfgang · 8 shared papers, 2014–2021 · strength 0.59
  11. Joseph M. Herman · 5 shared papers, 2014–2025 · strength 0.50
  12. Timothy Michael Pawlik · 3 shared papers, 2016–2025 · strength 0.32
  13. Jin Peng He · 3 shared papers, 2016–2021 · strength 0.27
  14. Ammar A. Javed · 3 shared papers, 2016–2021 · strength 0.26
  15. Dung Thi Le · 2 shared papers, 2018–2025 · strength 0.26
  16. Lauren M. Rosati · 2 shared papers, 2018–2025 · strength 0.26
  17. Amy Hacker‐Prietz · 2 shared papers, 2018–2025 · strength 0.26
  18. Christopher L. Wolfgang · 2 shared papers, 2018–2025 · strength 0.26
  19. Elizabeth M. Jaffee · 2 shared papers, 2018–2025 · strength 0.26
  20. Amol Kumar Narang · 2 shared papers, 2018–2025 · strength 0.26
  21. Daniel A. Laheru · 2 shared papers, 2018–2025 · strength 0.26
  22. Elliot K. Fishman · 4 shared papers, 2014–2018 · strength 0.25
  23. Colin Hill · 1 shared paper, 2025 · strength 0.20
  24. Lei Zheng · 1 shared paper, 2025 · strength 0.20
  25. Eric R. Lutz · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.